Drug Discovery Featured Articles & Applications

  1. End-to-end Technology Transfer Services In Oral Solids And Sterile
    3/29/2017

    In the pharmaceutical industry, “technology transfer” refers to the processes that are needed for successful progression of stages ranging from drug discovery, product development, clinical trials to full-scale commercialization or it is the transfer between development and commercialization at different sites within or outside an organization.

  2. Ozonolysis Development Solutions For Safety Studies And Scale Up
    3/29/2017

    Ozonolysis is a widely used reaction in organic synthesis. The reaction was invented by Christian Friedrich Schoenbein in 1840. Alkenes and alkynes are the most common substrates for the ozonolysis reaction. Ozonolysis was an important diagnostic tool for the determination of the position of unsaturation in unknown molecules before the invention and development of spectroscopic techniques for identification and characterization of organic molecules. The reaction was used for structure elucidation work because it provided chemists with smaller and more readily identifiable carbonyl compounds.

  3. Our Approach On Tech Transfer For Early Phase GMP Manufacturing
    3/29/2017

    Biotech firms often have tight timelines to prove the concept of their NCE. As a result, modern clinical development pathway requires rapid manufacturing of the “first Kilo”.

  4. The Upswing Of Sterile Injectables
    3/28/2017

    The $330 bn global sterile market is expected to reach $525 bn by 2020, growing at a CAGR of 11% -with North America contributing 48% while APAC is expected to record highest CAGR of 13%.

  5. Cross-Lab Data Collaborations – The Future Of Immunotherapy?
    3/22/2017

    In January, UC San Francisco announced a research alliance with AbbVie, Amgen, and BMS supporting the collection and analysis of at least 500 tumor samples from more than 10 different forms of cancer to ultimately improve patients’ responses to cancer immunotherapy.

  6. How To Ace Your FDA IND Submission (And How To Rebound If You Don’t)
    3/20/2017

    Let's assume you have your pre-IND ducks in a row. Now you're ready to embark on preparing and submitting the IND application to the FDA, which, if approved, will allow you to test your drug in humans for the first time. 

  7. What Outcomes-Based Contracts Mean For Drug Development And Drug Pricing
    3/17/2017

    The mounting public outcry over drug prices — fueled by dramatic increases in cost for a few high-profile, older, life-saving drugs — has put intense pressure on the pharmaceutical industry to lower prices.

  8. Broaden Analysis Of Compound Factors For Predictive Solubility Solutions
    3/2/2017

    Developed by the FDA, the Biopharmaceutics Classification System helps companies when they file for bioequivalence of dosage forms based on in vitro dissolution testing.

  9. Automation, Modularity Allow mAb Biotech To Cut Scale-Up Time
    2/14/2017

    Biomanufacturers, especially those facing the debut of biosimilars in core markets, have an urgent imperative to reduce manufacturing costs via increased productivity and yields. In turn, this drives a wide range of business decisions, including capital investment, process choices and design, and equipment selection. Learn how AlphaMab Co. Ltd, a fast-growing bio-developer and producer, cut scale-up time using a Quality by Design (QbD) approach.

  10. How Image Analysis Can Improve The Results Of Drug Development And Clinical Trials
    1/24/2017

    In recent years there have been several potentially life-saving medications approved for cancer treatment, including targeted molecular entities and biologics such as Opdivo (nivolumab) and Keytruda (pembrolizumab). Oncology drugs remain a pharmaceutical priority and investments into cancer account for 30% of all pre-clinical and phase 1 clinical development expenditures. There is an impressive list of close to 800 drugs and vaccines currently in the industry-wide development pipeline, many with promising results in early-stage clinical trials. However by historical measures only 10% or fewer of these drugs will ever make it through FDA approval and become part of routine patient care.